The anti-melanoma efficacy of the AZD6244-BEZ235 treatment was associated with strong inhibition of key signaling molecules, as documented by modulation of p-ERK and of p-AKT, both in-vitro and in-vivo. The gene discussed is AKT1; the disease is melanoma.